Search Medical Condition
Please enter condition
Please choose location

Burton-upon-Trent, United Kingdom Clinical Trials

A listing of Burton-upon-Trent, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (43) clinical trials

Prostate Adenocarcinoma TransCutaneous Hormones

OBJECTIVES Primary Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues. Secondary Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens Compare the activity of these treatments, in terms ...

Phase

0.0 miles

Learn More »

mHealth for Antenatal Mental Health

As part of our first aim, we will assess the psychometric properties of the Whooley questions, by comparing the answers given to these questions against the scores obtained on the Edinburgh Postnatal Depression Scale, and we will manipulate the survey questionnaire layout of the Whooley Questions and the Edinburgh Postnatal ...

Phase N/A

0.0 miles

Learn More »

MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma

Mesothelioma is a cancer of the thin membrane that lines the chest and abdomen. Around 2300 people in the UK are diagnosed with mesothelioma each year and the average survival is approximately 17 months. Exposure to asbestos is the most common cause although the cancer does not usually become apparent ...

Phase N/A

0.0 miles

Learn More »

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-nave prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control ...

Phase

0.0 miles

Learn More »

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Chlorambucil (Chl) has been the mainstay of CLL treatment for half a century. However, frontline treatment has improved considerably over the last decade, first by the advent of fludarabine plus cyclophosphamide (FC), and more recently by the addition of the anti-CD20 antibody, rituximab, to FC. Although FC-based regimens are considerably ...

Phase

0.0 miles

Learn More »

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

OBJECTIVES: - Determine the percentage of patients with relapsed advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma who have a log linear rise in CA 125 levels. - Determine whether the log linear part of the curve is consistent enough to allow comparison of the slope before and ...

Phase

0.8 miles

Learn More »

Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)

Everyone who agrees to take part will have a short specialist MRI scan, called diffusion weighted MRI, to look for cancer in the liver. Normally you will have this scan within 4 weeks of joining the study. You will be able to start your cancer treatment while you are in ...

Phase N/A

0.8 miles

Learn More »

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

This is a non-interventional, multicenter, prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with mCRPC, based on documented metastatic prostate cancer and documented castration resistance. Castrate-resistant prostate cancer is defined by disease progression despite testosterone <50 ng/dL, and/or androgen deprivation therapy, and/or a history ...

Phase N/A

0.8 miles

Learn More »

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple myeloma is the second most common hematologic malignancy in the European Union (EU), responsible for an estimated 21,000 deaths in the EU in 2008. For patients that relapse or are refractory to current standard treatment (combination of bortezomib/lenalidomide, dexamethasone and an alkylating agent) there are few options available and ...

Phase

0.8 miles

Learn More »

Studying DNA in Patients With Stage I Stage II Stage III or Stage IV Ovarian Epithelial Cancer

OBJECTIVES: - To determine if DNA methylation patterns and expression of differentially methylated genes taken before chemotherapy can predict patient outcome with regard to progression-free survival. - To evaluate whether DNA methylation can predict response assessed by RECIST criteria and CA 125 response. - To evaluate the specificity and sensitivity ...

Phase N/A

0.8 miles

Learn More »